Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImageneBio, Inc.

ImageneBio, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.105 USD -0.06 ( 1.44%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1401
Market Cap
55.85M

Momentum Score

…

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.04
Low
4.26
High
52 Week Price Range
3.94
Low
9.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ImageneBio, Inc. is a Nasdaq-listed company with limited publicly available information about its business and programs. It appears positioned in the early-stage life-sciences/biotechnology area and may benefit from successful development milestones, potential licensing or partnership activity, and broader sector interest in innovative therapeutic approaches. Investors may find appeal in upside tied to program validation and clinical catalysts while recognizing typical biotech binary outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.17
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.08
ROE
-82.68%
Net Debt
-24.97M
ROCE
-32.24%
Diluted EPS TTM
-4.73

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -45.70M -36.55M -68.33M -68.77M -34.12M
Net income -45.35M -36.57M -68.17M -68.77M -34.12M
Selling general administrative 20.73M 8.39M 24.93M 22.20M 18.02M
Gross profit -0.23M 1.97M 8.14M -48.70M -16.12M
Reconciled depreciation 1.03M 1.53M 3.10M - -
Ebit -45.70M -36.55M -68.33M -68.77M -34.12M
Ebitda -44.67M -35.03M -67.31M -68.01M -33.57M
Depreciation and amortization 1.03M 1.53M 1.02M 0.75M 0.54M
Operating income -48.45M -37.00M -75.42M -70.90M -34.14M
Other operating expenses 49.25M 40.50M 84.58M 86.52M 65.12M
Tax provision -0.35M 0.01M 0.28M - -
Interest income - 0.37M 1.19M - -
Net interest income 2.04M 0.37M 1.19M - -
Income tax expense -0.35M 0.01M -0.16M -2.14M 0.31M
Total revenue 0.80M 3.50M 9.16M 15.62M 30.98M
Total operating expenses 48.22M 38.97M 83.56M 22.20M 18.02M
Cost of revenue 1.03M 1.53M 1.02M 64.32M 47.11M
Total other income expense net 2.75M 0.45M 7.09M 2.14M 0.02M
Net income from continuing ops -45.35M -36.57M -21.15M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 152.98M 141.51M 192.09M 172.26M 247.88M
Other current assets 63.21M 2.78M 3.20M 3.06M 4.30M
Total liab 19.84M 15.58M 22.34M 25.29M 40.00M
Total stockholder equity 133.14M 125.93M 169.76M 146.97M 207.88M
Other current liab 7.53M 6.10M 8.58M 8.34M 5.85M
Common stock 0.01M 0.05M 0.05M 0.04M 0.04M
Capital stock 0.01M 18.98M 18.98M - -
Retained earnings -230.05M -331.62M -282.38M -214.22M -145.45M
Cash 34.97M 39.39M 119.89M 59.92M 232.22M
Total current liabilities 11.23M 10.78M 14.21M 21.50M 27.19M
Current deferred revenue - - - 9.16M 17.10M
Net debt -24.97M -31.87M -109.16M -54.23M -225.23M
Short term debt 2.26M 3.78M 3.56M 1.91M 1.85M
Short long term debt - 7.50M - - -
Short long term debt total 9.99M 7.52M 10.74M 5.69M 6.99M
Other stockholder equity 363.09M 457.44M 452.14M 361.92M 353.30M
Total current assets 140.29M 127.17M 178.66M 160.01M 236.52M
Long term investments 0.00M 0.94M 0.94M - -
Short term investments 40.82M 84.99M 55.57M 97.03M -
Net receivables 1.30M - - - -
Accounts payable 1.44M 0.90M 2.07M 2.09M 2.38M
Accumulated other comprehensive income 0.09M 0.07M -0.05M -0.76M -247.88M
Non currrent assets other 11.90M 10.11M 5.41M 3.79M 2.39M
Non current assets total 12.69M 14.34M 13.43M 12.25M 11.36M
Capital lease obligations 2.98M 0.55M 0.98M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.60M 11.12M -10.45M - -
Total cashflows from investing activities -5.81M -34.90M 64.14M -99.28M -1.76M
Net borrowings 15.00M 7.50M 0.00M - -
Total cash from financing activities 135.47M 6.91M 75.98M 1.09M 131.74M
Net income -52.40M -49.23M -68.17M -68.77M -34.12M
Change in cash 82.41M -80.91M 59.98M -172.30M 69.73M
Begin period cash flow 12.12M 121.17M 59.92M 233.09M 163.36M
End period cash flow 94.53M 40.27M 119.89M 60.79M 233.09M
Total cash from operating activities -47.84M -46.00M -79.74M -74.11M -60.25M
Issuance of capital stock 71.13M 0.00M - - -
Depreciation 0.33M 0.49M 1.02M 0.75M 0.54M
Other cashflows from investing activities -5.21M -7.07M - -97.85M -
Change to inventory - - - - -0.36M
Change to account receivables - - -2.87M -0.29M 0.36M
Sale purchase of stock - - -0.66M - -
Other cashflows from financing activities 54.63M - 39.09M 1.09M 0.44M
Capital expenditures 0.00M 0.00M 0.41M 1.43M 1.76M
Change in working capital -19.19M -3.98M -21.67M -15.14M -33.03M
Stock based compensation 15.39M 5.29M 7.63M 7.53M 5.18M
Other non cash items 8.02M 1.42M 9.07M 1.52M 1.17M
Free cash flow -47.84M -46.00M -80.16M -75.54M -62.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
IMA
ImageneBio, Inc.		 -0.06
1.44%		 4.11 - - 83.32 0.40 31.86
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

12526 High Bluff Drive, San Diego, CA, United States, 92130

858 345 6265

https://www.inmagenebio.com

18

Name Title Year Born
Dr. Kristin Yarema Ph.D. CEO & Director 1971
Ms. Yanina Grant-Huerta CFO, Principal Financial Officer & Principal Accounting Officer 1977
Dr. Kurinji Pandiyan Ph.D. Chief Strategy & Operations Officer NA
Ms. Renuka Sivendran Ph.D. Chief Technical Officer NA
Mr. Matt Robbins J.D. General Counsel NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…